Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefotiam Hydrochloride

FDA-approved product (injectable, injection), marketed as Ceradon.

Registered studies
2
Lab records
1
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cefotiam Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Second-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DC07

Repurposing investigation

Cefotiam Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli90.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

2registered studies name this medicine, for any condition. See them below.

Experimental

  • K. pneumoniae: measured active in 0 of 1 lab record
Open Cefotiam Hydrochloride in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefotiam Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices

    NCT03045783 · start 2016-12

    Registered record
    Registry ID
    NCT03045783
    Conditions
    Gastric Varices; Cirrhosis
    Interventions
    Cefotiam
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-12
    Completion
    2019-07
    Enrolment
    912

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Varices; Cirrhosis
    InterventionCefotiam
    PhaseNot applicable
    Registry statusUnknown

  • Efficiency and Safety of Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices

    NCT02693951 · start 2016-02

    Registered record
    Registry ID
    NCT02693951
    Conditions
    Gastric Varices; Cirrhosis
    Interventions
    Cefotiam
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-02
    Completion
    2017-09
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Varices; Cirrhosis
    InterventionCefotiam
    PhaseNot applicable
    Registry statusUnknown